Literature DB >> 7788622

Screening for post-partum depression in a community sample.

P Zelkowitz1, T H Milet.   

Abstract

OBJECTIVE: This study undertook to estimate the prevalence of post-partum depression in the community by means of telephone screening. Demographic correlates of post-partum depression were also investigated.
METHOD: The sample was identified through two community health centres. Over a period of 17 months, 1559 childbearing women were screened at six weeks post-partum, using the ten-item Edinburgh Postnatal Depression Scale (EPDS).
RESULTS: The prevalence of post-partum depression was estimated to be 6.2%, using a cut point of 10 on the EPDS, and 3.4% using the more stringent cut point of 12. Women who were not working or those with lower occupational status, were at greater risk for depression. Recent immigrants, particularly those who were not working or who had given birth to a second child, were also at higher risk.
CONCLUSION: Telephone screening for post-partum depression is feasible, and can aid in the identification of women at risk.

Entities:  

Mesh:

Year:  1995        PMID: 7788622     DOI: 10.1177/070674379504000205

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  22 in total

1.  Assessing the quality of diagnostic studies using psychometric instruments: applying QUADAS.

Authors:  Rachel Mann; Catherine E Hewitt; Simon M Gilbody
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-10-04       Impact factor: 4.328

2.  The validity of the Arabic Edinburgh Postnatal Depression Scale.

Authors:  R Ghubash; M T Abou-Saleh; T K Daradkeh
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  1997-11       Impact factor: 4.328

Review 3.  Examining the Social Patterning of Postpartum Depression by Immigration Status in Canada: an Exploratory Review of the Literature.

Authors:  Megan Saad
Journal:  J Racial Ethn Health Disparities       Date:  2018-09-19

4.  An intervention to reduce postpartum depressive symptoms: a randomized controlled trial.

Authors:  Elizabeth A Howell; Susan Bodnar-Deren; Amy Balbierz; Holly Loudon; Pablo A Mora; Caron Zlotnick; Jason Wang; Howard Leventhal
Journal:  Arch Womens Ment Health       Date:  2013-09-10       Impact factor: 3.633

5.  The association of stillbirth with depressive symptoms 6-36 months post-delivery.

Authors:  Carol J R Hogue; Corette B Parker; Marian Willinger; Jeff R Temple; Carla M Bann; Robert M Silver; Donald J Dudley; Janet L Moore; Donald R Coustan; Barbara J Stoll; Uma M Reddy; Michael W Varner; George R Saade; Deborah Conway; Robert L Goldenberg
Journal:  Paediatr Perinat Epidemiol       Date:  2015-02-14       Impact factor: 3.980

6.  Predicting changes in depressive symptoms from pregnancy to postpartum: the role of brooding rumination and negative inferential styles.

Authors:  Sarah E Barnum; Mary L Woody; Brandon E Gibb
Journal:  Cognit Ther Res       Date:  2013-02

Review 7.  Role of estrogen in the aetiology and treatment of mood disorders.

Authors:  U Halbreich; L S Kahn
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

8.  Factors associated with clinically significant insomnia among pregnant low-income Latinas.

Authors:  Rachel Manber; Dana Steidtmann; Andrea S Chambers; William Ganger; Sarah Horwitz; Cynthia D Connelly
Journal:  J Womens Health (Larchmt)       Date:  2013-07-17       Impact factor: 2.681

9.  Is screening for depression in the perinatal period enough? The co-occurrence of depression, substance abuse, and intimate partner violence in culturally diverse pregnant women.

Authors:  Cynthia D Connelly; Andrea L Hazen; Mary J Baker-Ericzén; John Landsverk; Sarah McCue Horwitz
Journal:  J Womens Health (Larchmt)       Date:  2013-08-09       Impact factor: 2.681

10.  Effect of peer support on prevention of postnatal depression among high risk women: multisite randomised controlled trial.

Authors:  C-L Dennis; E Hodnett; L Kenton; J Weston; J Zupancic; D E Stewart; A Kiss
Journal:  BMJ       Date:  2009-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.